AstraZeneca raised its sales and profit outlook for the year thanks to strong demand for its cancer drugs and announced a deal to develop an obesity drug that could be given in tablet form rather than as injections.
由于抗癌药需求强劲，阿斯利康(AstraZeneca)上调了今年的销售和利润预期，并宣布一项协议，将开发一种可以片剂而非注射剂方式给药的减肥药。
您已阅读7%（287字），剩余93%（3542字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。